In this bi-institutional study, twenty-three stage IIIC-IV MAGE-A3+ melanoma patients were vaccinated with M3TK-GML biweekly at three dose levels, with a subsequent phase of vaccinations at the maximum dose level. Anti-MAGE-A3 and anti-TK T cells were as-sessed by in vitro assay and delayed-type hypersensitivity skin testing. © Ivyspring International Publisher.
A clinical study of a cell-based MAGE-A3 active immunotherapy in advanced melanoma patients / Russo, V.; Lunghi, F.; Fontana, R.; Bregni, M.. - In: JOURNAL OF CANCER. - ISSN 1837-9664. - 2:1(2011), pp. 329-330. [10.7150/jca.2.329]
A clinical study of a cell-based MAGE-A3 active immunotherapy in advanced melanoma patients
Russo V.;Fontana R.;
2011-01-01
Abstract
In this bi-institutional study, twenty-three stage IIIC-IV MAGE-A3+ melanoma patients were vaccinated with M3TK-GML biweekly at three dose levels, with a subsequent phase of vaccinations at the maximum dose level. Anti-MAGE-A3 and anti-TK T cells were as-sessed by in vitro assay and delayed-type hypersensitivity skin testing. © Ivyspring International Publisher.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
